Peptron, Inc. (087010.KQ)
KRW 98300.0
(-1.99%)
KRW 98300.0
(-1.99%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 16.36 Billion KRW | 7.94% |
| 2022 | 15.16 Billion KRW | -2.7% |
| 2021 | 15.58 Billion KRW | -61.58% |
| 2020 | 40.56 Billion KRW | 23.31% |
| 2019 | 32.89 Billion KRW | 23.4% |
| 2018 | 26.66 Billion KRW | 549.7% |
| 2017 | 4.1 Billion KRW | -12.56% |
| 2016 | 4.69 Billion KRW | 5.96% |
| 2015 | 4.42 Billion KRW | 0.77% |
| 2014 | 4.39 Billion KRW | -60.09% |
| 2013 | 11.01 Billion KRW | 4.92% |
| 2012 | 10.49 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 17.81 Billion KRW | 8.82% |
| 2024 Q2 | 16.57 Billion KRW | -6.98% |
| 2023 Q3 | 15.28 Billion KRW | 1.52% |
| 2023 Q1 | 14.82 Billion KRW | -2.25% |
| 2023 Q2 | 15.05 Billion KRW | 1.54% |
| 2023 FY | 16.36 Billion KRW | 7.94% |
| 2023 Q4 | 16.36 Billion KRW | 7.12% |
| 2022 Q4 | 15.16 Billion KRW | -2.35% |
| 2022 Q3 | 15.53 Billion KRW | -3.39% |
| 2022 Q2 | 16.07 Billion KRW | 5.54% |
| 2022 FY | 15.16 Billion KRW | -2.7% |
| 2022 Q1 | 15.23 Billion KRW | -2.27% |
| 2021 Q4 | 15.58 Billion KRW | 13.68% |
| 2021 FY | 15.58 Billion KRW | -61.58% |
| 2021 Q2 | 40.9 Billion KRW | 0.76% |
| 2021 Q3 | 13.71 Billion KRW | -66.48% |
| 2021 Q1 | 40.59 Billion KRW | 0.06% |
| 2020 Q1 | 33.48 Billion KRW | 1.77% |
| 2020 Q4 | 40.56 Billion KRW | 0.29% |
| 2020 Q2 | 35.27 Billion KRW | 5.36% |
| 2020 Q3 | 40.45 Billion KRW | 14.67% |
| 2020 FY | 40.56 Billion KRW | 23.31% |
| 2019 Q3 | 24.13 Billion KRW | -1.48% |
| 2019 Q2 | 24.49 Billion KRW | -10.26% |
| 2019 Q1 | 27.29 Billion KRW | 2.37% |
| 2019 FY | 32.89 Billion KRW | 23.4% |
| 2019 Q4 | 32.89 Billion KRW | 36.33% |
| 2018 Q1 | 22.13 Billion KRW | 439.47% |
| 2018 FY | 26.66 Billion KRW | 549.7% |
| 2018 Q3 | 27.76 Billion KRW | -0.62% |
| 2018 Q2 | 27.93 Billion KRW | 26.21% |
| 2018 Q4 | 26.66 Billion KRW | -3.99% |
| 2017 Q3 | 4.6 Billion KRW | 0.02% |
| 2017 Q4 | 4.1 Billion KRW | -10.81% |
| 2017 FY | 4.1 Billion KRW | -12.56% |
| 2017 Q1 | 4.62 Billion KRW | -1.38% |
| 2017 Q2 | 4.6 Billion KRW | -0.61% |
| 2016 Q2 | 5 Billion KRW | 13.88% |
| 2016 Q1 | 4.39 Billion KRW | 50.78% |
| 2016 FY | 4.69 Billion KRW | 5.96% |
| 2016 Q4 | 4.69 Billion KRW | -7.22% |
| 2016 Q3 | 5.05 Billion KRW | 1.16% |
| 2015 Q4 | 2.91 Billion KRW | 0.32% |
| 2015 Q2 | 2.96 Billion KRW | -31.22% |
| 2015 Q1 | 4.3 Billion KRW | 0.0% |
| 2015 FY | 4.42 Billion KRW | 0.77% |
| 2015 Q3 | 2.9 Billion KRW | -2.04% |
| 2014 Q1 | - KRW | 0.0% |
| 2014 FY | 4.39 Billion KRW | -60.09% |
| 2013 FY | 11.01 Billion KRW | 4.92% |
| 2012 FY | 10.49 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Co., Ltd. | 169.47 Billion KRW | 90.341% |
| iNtRON Biotechnology, Inc. | 1.88 Billion KRW | -770.522% |
| BINEX Co., Ltd. | 75.68 Billion KRW | 78.373% |
| Bioneer Corporation | 80.61 Billion KRW | 79.694% |
| Anterogen.Co.,Ltd. | 19.98 Billion KRW | 18.101% |
| MEDIPOST Co., Ltd. | 135.73 Billion KRW | 87.941% |
| CrystalGenomics, Inc. | 97.82 Billion USD | 83.267% |
| Helixmith Co., Ltd | 73.55 Billion KRW | 77.747% |
| Chabiotech Co.,Ltd. | 1069.23 Billion KRW | 98.469% |
| Medy-Tox Inc. | 137.14 Billion KRW | 88.064% |
| Amicogen, Inc. | 248.12 Billion KRW | 93.403% |
| Genexine, Inc. | 79.68 Billion KRW | 79.457% |
| HLB Therapeutics Co.,Ltd. | 29.27 Billion KRW | 44.087% |
| LegoChem Biosciences, Inc. | 41.28 Billion KRW | 60.347% |
| ALTEOGEN Inc. | 108.25 Billion KRW | 84.88% |
| PharmaResearch Co., Ltd. | 73.08 Billion KRW | 77.603% |
| SillaJen, Inc. | 19.4 Billion KRW | 15.628% |
| JETEMA, Co., Ltd. | 179.09 Billion KRW | 90.86% |
| OliX Pharmaceuticals,Inc | 52.48 Billion KRW | 68.815% |
| Genomictree Inc. | 7.81 Billion KRW | -109.529% |
| MedPacto, Inc. | 9.56 Billion KRW | -71.121% |
| D&D Pharmatech | 23.98 Billion KRW | 31.755% |
| EASY BIO,Inc. | 105.86 Billion KRW | 84.538% |
| GI Innovation, Inc. | 9.63 Billion KRW | -69.869% |